Which of the following describes a consequence of Fenofibrate's mechanism of action?

Fenofibrate is a medication primarily used to reduce triglyceride levels and improve overall lipid profiles in patients. Its mechanism of action involves the activation of peroxisome proliferator-activated receptor alpha (PPAR-α), which leads to several important effects on lipid metabolism.

By activating PPAR-α, Fenofibrate enhances the expression of genes involved in lipid metabolism, particularly those that increase the activity of lipoprotein lipase (LPL). This increased activity promotes the breakdown of triglyceride-rich lipoproteins, facilitating enhanced lipolysis. As a consequence, the drug helps to lower the levels of triglycerides in the bloodstream.

Moreover, the activation of PPAR-α also leads to increased cholesterol efflux, modulation of fatty acid oxidation, and decreased production of apoprotein C-III, which normally inhibits the action of LPL. Therefore, the correct answer indicates that Fenofibrate's action results in enhanced lipolysis of triglyceride-rich particles, directly contributing to its efficacy in managing dyslipidemia.

This understanding of Fenofibrate’s mechanism emphasizes its role in improving lipid metabolism and lowering triglyceride levels, highlighting why the enhanced lipolysis of triglyceride-rich particles is a significant consequence of its action.